A case report from researchers at the University of Colorado Anschutz Medical Campus in Aurora links tirzepatide, sold as Zepbound, to lithium toxicity in a 50-year-old woman with bipolar disorder. It is the fourth reported case of tirzepatide-associated lithium toxicity,…
GLP-1s
Adults with schizophrenia and Type 2 diabetes who started a glucagon-like peptide-1 receptor agonist were less likely to be hospitalized or seen in the emergency department for psychiatric reasons than peers who started a dipeptidyl peptidase-4 inhibitor, a sodium-glucose cotransporter-2…
Santa Fe, N.M.-based Quel Health launched a telehealth platform focused on using GLP-1 receptor agonists in addiction care. The platform is available in 41 states and the District of Columbia, with national coverage planned by year-end, according to a Sept. 8 news…
The U.S. Department of Veterans Affairs is launching a clinical trial to evaluate whether semaglutide, a GLP-1 receptor agonist used to treat diabetes, can treat alcohol use disorder among veterans, according to a July 30 news release. The trial comes…
GLP-1 receptor agonists are gaining traction in addiction treatment, though the lack of FDA approval and long-term data continues to limit widespread adoption, Mo Sarhan, MD, medical director of addiction medicine for Delray Beach, Fla.-based Caron Treatment Centers, told Becker’s.…
Advertisement
New Haven, Conn.-based Yale researchers are studying whether GLP-1 drugs may extend beyond diabetes and obesity treatment to address addiction, NBC Connecticut reported March 27. Rajita Sinha, PhD, director of the Yale Interdisciplinary Stress Center, studied semaglutide in people with…
The American Dental Association has updated patient health history forms to include a mental health screening question and a prompt about GLP-1 receptor agonists. The ADA Council on Dental Practice approved the changes in January, according to a March 24…